Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
NervGen Pharma Corp. (NGEN) had Stock-Based Compensation of 0.69M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
-1.22M |
|
-- |
|
-- |
|
5.49M |
|
-5.49M |
|
4.27M |
|
-1.22M |
|
-1.22M |
|
-1.22M |
|
-1.22M |
|
-1.22M |
|
-1.22M |
|
-5.49M |
|
-5.48M |
|
79.90M |
|
80.86M |
|
-0.01 |
|
-0.07 |
|
| Balance Sheet Financials | |
14.85M |
|
-- |
|
0.29M |
|
15.14M |
|
11.10M |
|
-- |
|
-- |
|
11.10M |
|
4.04M |
|
3.75M |
|
4.04M |
|
80.99M |
|
| Cash Flow Statement Financials | |
-5.98M |
|
0.01M |
|
2.03M |
|
16.09M |
|
12.07M |
|
-4.02M |
|
|
Stock-Based Compensation |
0.69M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.98M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-30.24% |
|
-32.56% |
|
-8.07% |
|
-30.24% |
|
0.05 |
|
-0.07 |
|
-0.07 |
|